A Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects With Normal Tension Glaucoma (NTG)
Latest Information Update: 01 Oct 2025
At a glance
- Drugs QLS 111 (Primary)
- Indications Low tension glaucoma
- Focus Adverse reactions
- Acronyms Nightingale
- Sponsors Qlaris Bio
Most Recent Events
- 29 Aug 2025 Planned End Date changed from 30 Nov 2025 to 30 Dec 2025.
- 29 Aug 2025 Planned primary completion date changed from 15 Nov 2025 to 1 Dec 2025.
- 29 Aug 2025 Status changed from not yet recruiting to recruiting.